ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
April 04, 2020Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell & gene therapy company, is pleased to announce that China National Medical Products Administration (NMPA) has accepted Gracell's Investigational New Drug (IND) application for GC -
Yisheng Biopharma receives approval from China NMPA for rabies vaccine production facility
July 23, 2019The vaccine has demonstrated effective protection, contributing to the fight against rabies infection.
Pharma Sources Insight January 2025
